Cellebrite is unlikely to return to 25% ARR growth, so its cheap valuation will not expand until revenue reaccelerates. It depends too heavily on the US government, unlike Axon, which is diversifying into states and commercial. Its edge was unlocking iPhones, but its evidence-management platform is sticky without a moat, and breaching phones gets harder with each iOS version. Repeated misses with new excuses are worrying, even if guidance looks sandbagged and deal delays are only ~6 weeks. x.com  … Show more

Cellebrite's guidance cut looks like kitchen-sinking expectations to give the new CEO a low base, setting up a beat and re-raise. On the call, 4-5 major deals slipped a quarter and Genesis is ramping slower than expected, but new products are growing over 25%, FedRAMP is a tailwind, and US federal barely grew last year. A Q3 beat and re-raise could take the stock back to $16, a 50% return in a quarter. If deal closings do not speed up in Q3, the recovery takes longer, but risk-reward looks good. … Show more